NimBio
NimBio is an early-stage Amsterdam-based digital health company building the Inflammometer, an AI-driven wearable platform that uses PPG waveform analysis to continuously monitor inflammation and predict IBD flares for patients, clinicians, pharmaceutical companies, and payers across Europe.
- Company typePrivate
- Founded2023
- HeadquartersAmsterdam, Netherlands
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What NimBio does
NimBio is an early-stage digital health company, founded in 2023 and headquartered in Amsterdam, that builds an AI-driven wearable inflammation monitoring platform aimed at Inflammatory Bowel Disease patients. Its core product, the Inflammometer, uses photoplethysmography (PPG) waveform analysis captured through everyday wearables to provide continuous, non-invasive tracking of inflammatory status and to deliver early warning of impending IBD flares before symptoms manifest. Companion smartwatch and tablet interfaces surface real-time inflammation status to patients, while a backend platform attributes flare causes such as treatment failure or poor adherence and generates therapeutic recommendations.
Underlying capabilities combine passive bio-sensing with predictive AI spanning anomaly detection, flare forecasting, and treatment optimization, validated through a completed clinical proof-of-concept and ongoing studies across three medical centers. The company has presented its PPG-based approach at the ECCO'24 Congress and as an oral lecture at DDW2024, and is supported by the eHealth Ventures portfolio with disclosed investment from European VC Venturing Holding BV.
NimBio operates a B2B2C model serving four segments: IBD patients (consumers of the wearable and app), hospitals and physicians (remote patient monitoring), pharmaceutical companies (treatment optimization and real-world evidence), and payers or insurers (hospitalization reduction). Pricing is not publicly disclosed; the go-to-market is enterprise-led, anchored by an April 2025 memorandum of understanding with Takeda Belgium, KU Leuven, and EIT Health to launch clinical pilots, with marketing concentrated in healthcare conferences (HLTH, ECCO, DDW) and category-defining award platforms such as the EIT Health Catapult. The company is private, pre-revenue in disclosed terms, and currently active in the Netherlands and Belgium, with US-facing activity beginning in 2025.
NimBio firmographics
Firmographics- Name
- NimBio
- Legal name
- Nimbio
- Website
- https://nimbio.ai
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- NimBio is an early-stage Amsterdam-based digital health company building the Inflammometer, an AI-driven wearable platform that uses PPG waveform analysis to continuously monitor inflammation and predict IBD flares for patients, clinicians, pharmaceutical companies, and payers across Europe.
- Ownership category
- akta.pro rank
NimBio industry classification
Industry- Product category
- Digital Health / Remote Patient Monitoring
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Inflammatory Bowel Disease (IBD) Care (HLAKAEAD)
- akta.pro secondary industry
- Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where NimBio is headquartered
LocationHeadquarters
- HQ city
- Amsterdam
- HQ country
- Netherlands
- HQ region
- Europe
Offices1 record
Markets served
NimBio business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Healthcare Monitoring Platform: B2B2C model providing inflammation monitoring services to healthcare providers, pharma companies, and payers. Revenue likely derives from platform licensing, per-patient monitoring fees, and outcomes-based contracts with payers.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
NimBio product offering
Product offeringCore offering
NimBio develops and sells the Inflammometer, an AI-driven, wearable-powered inflammation monitoring platform that uses passive bio-sensing and photoplethysmography (PPG) waveform analysis to continuously track inflammation biomarkers in patients with Inflammatory Bowel Disease (IBD). The platform identifies flare-up causes (treatment failure, poor adherence) and offers real-time therapeutic recommendations for healthcare providers, pharmaceutical companies, and payers.
Product overview
NimBio offers a unified remote care solution for Inflammatory Bowel Disease (IBD) patients consisting of the Inflammometer (wearable-powered AI inflammation monitor) and the NimBio Platform. The Inflammometer is a wearable device that uses passive bio-sensing to continuously track inflammation biomarkers and provide real-time inflammation status, while the NimBio Platform analyzes this data to identify flare-up causes and deliver personalized therapeutic recommendations. The solution includes smartwatch and tablet UI components for patient interaction. The company is conducting clinical validation studies across multiple medical centers.
Differentiator
Problem solved
Functional benefit
Brands
- Inflammometer: A wearable-powered, AI-driven inflammation monitor that provides continuous tracking of inflammation levels through everyday wearables, detecting early warning signs of IBD flares before symptoms appear.
Products and services
- Inflammometer A wearable-powered, AI-driven inflammation monitor that continuously tracks inflammation levels through everyday wearables using passive bio-sensing, providing real-time inflammation status and detecting early warning signs of IBD flares before symptoms appear. Designed for IBD patients, healthcare providers, and pharmaceutical partners.
- NimBio Platform A remote care platform that integrates wearable bio-sensing data to identify flare-up causes (such as treatment failure or poor medical adherence) and offers therapeutic recommendations in real time. Provides personalized early flare detection for healthcare providers, pharma companies, and payers managing IBD patient populations.
Quantifiable outcome
- Successfully completed clinical POC study with ongoing validation at three medical centers
- +1 more outcomes
Companies that use NimBio
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles3 records
NimBio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature4 records
NimBio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- EIT HealthcoreEIT Health Open Innovation programme selected NimBio as finalist and supported the partnership with Takeda Belgium and KU Leuven. EIT Health brought together healthcare providers and industry experts to identify urgent unmet needs, facilitating NimBio's clinical pilot program. The organization continues to provide mentorship and platform access through the Catapult program.
- Takeda BelgiumcoreTakeda Belgium partnered with NimBio following the EIT Health IBD Challenge. They highlighted the shared challenge of detecting IBD flares earlier and enabling more personalized, proactive care. Takeda will explore integration with their 'For You With You' digital platform. A Memorandum of Understanding (MoU) was signed to launch a clinical pilot testing the Inflammometer.
- KU LeuvencoreKU Leuven is a key academic partner in the clinical pilot program, providing real-world hospital setting for testing the Inflammometer with actual patients. As a leading European research university with strong medical faculty, KU Leuven brings clinical expertise and patient access for validation studies.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
NimBio competitors and assessment
Company assessmentBroad incumbents
- Huma: Digital health platform for remote patient monitoring and decentralized clinical trials, used by major pharma and health systems. Comparable in RPM and predictive analytics capabilities, broader in therapeutic coverage.
- WellDoc: Pioneer in digital therapeutics and chronic disease management platforms (with FDA-cleared products). Comparable as a regulated, B2B-focused digital health platform addressing chronic conditions.
- Biofourmis: Established remote patient monitoring and predictive analytics platform spanning multiple therapeutic areas using wearable biosensors and AI. Comparable technology stack (wearables + AI + RPM) but operates broadly rather than IBD-specific.
Direct peers
- Oshi Health: Virtual-first gastroenterology care platform combining digital tools with clinician support for IBD/IBS patients, sold to payers and employers. Comparable in disease focus, multi-stakeholder value proposition, and B2B2C economics.
- Vivante Health: Digital GI health platform offering condition management, nutrition, and remote monitoring for IBD and IBS patients via B2B payer/employer channels. Highly comparable in disease focus, target population, and enterprise GTM motion.
- Mahana Therapeutics: Developer of prescription digital therapeutics for GI conditions including IBS, with regulatory-cleared software products addressing gut-brain interaction. Comparable as a digital therapeutic targeting the same patient population.
- Trellus Health: Digital health platform specifically focused on IBD and other immune-mediated conditions, providing resilience-based care and remote monitoring. Closest direct comparable to NimBio given overlapping IBD focus and B2B2C enterprise model.
Emerging players
- Ayble Health: Digital health platform for IBD and IBS combining behavioral, dietary, and clinical support. Comparable as an emerging GI-focused digital health company with similar B2B2C ambitions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
NimBio social profiles
Digital presenceNimBio financial estimates
Financial estimateRevenue estimate
Valuation estimate
NimBio leadership team
Management profileNumber of profiles
Profiles2 records
NimBio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NimBio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NimBio
What does NimBio do?
NimBio develops and sells the Inflammometer, an AI-driven, wearable-powered inflammation monitoring platform that uses passive bio-sensing and photoplethysmography (PPG) waveform analysis to continuously track inflammation biomarkers in patients with Inflammatory Bowel Disease (IBD). The platform identifies flare-up causes (treatment failure, poor adherence) and offers real-time therapeutic recommendations for healthcare providers, pharmaceutical companies, and payers.
Is NimBio a public or private company?
NimBio is a private company. It is classified as venture growth investor backed and is currently operating.
When was NimBio founded?
NimBio was founded in 2023. It employs 1 to 10 people.
Where is NimBio based?
NimBio is headquartered in Amsterdam, Netherlands, in the Europe region.
How does NimBio make money?
One revenue line is on record: healthcare Monitoring Platform.
Who are NimBio's main competitors?
Broad incumbents on record are Huma, WellDoc and Biofourmis. Direct peers are Oshi Health, Vivante Health, Mahana Therapeutics and Trellus Health. Ayble Health is listed as an emerging player.
Does NimBio have an API?
No public API is recorded for NimBio.
What industry is NimBio in?
NimBio's product category is Digital Health / Remote Patient Monitoring. Its primary akta.pro industry code is HLAKAEAD, Inflammatory Bowel Disease (IBD) Care, with a secondary code of HLAAALAO, Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays). Its NAICS code is 334510 and its SIC code is 3845.